NCT03151213

Brief Summary

The study aimed to investigate the preemptive analgesia efficacy of of preemptive pregabalin for the postoperative pain management after radiofrequency ablation (RFA) of liver cancer.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Jan 2017

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2017

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

May 11, 2017

Completed
1 day until next milestone

First Posted

Study publicly available on registry

May 12, 2017

Completed
20 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2017

Completed
29 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2017

Completed
Last Updated

March 13, 2026

Status Verified

March 1, 2026

Enrollment Period

5 months

First QC Date

May 11, 2017

Last Update Submit

March 11, 2026

Conditions

Hepatocellular Cancer

Outcome Measures

Primary Outcomes (1)

  • visual analogue pain scale (VAS Pain) post operatively

    Amplitude of pain postoperatively

    2 weeks

Study Arms (2)

Pregabalin

ACTIVE COMPARATOR

Pregabalin 150 mg before intervention

Drug: Pregabalin 150mg

Placebo

PLACEBO COMPARATOR

Placebo before intervention

Other: Placebo

Interventions

Pregabalin 150mgDRUG

Pregabalin 150mg before RFA of liver cancer

Also known as: pregab
Pregabalin
PlaceboOTHER

Placebo before RFA of liver cancer

Placebo

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • HCC patients, Child A, B, scheduled for Radiofrequency ablation of HCC.

You may not qualify if:

  • Encephalopathy, Renal impairment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tanta university - faculty of medicine

Cairo, Elgharbia, Egypt

Location

MeSH Terms

Conditions

Liver Neoplasms

Interventions

Pregabalin

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesLiver Diseases

Intervention Hierarchy (Ancestors)

gamma-Aminobutyric AcidAminobutyratesButyratesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsAmino AcidsAmino Acids, Peptides, and Proteins

Study Officials

  • Amr Magdy Abdelfattah, consultant

    Tanta University Faculty of Medicine

    PRINCIPAL INVESTIGATOR

  • Sherief Abd-Elsalam, Consultant

    Tanta university Faculty of Medicine

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Masking Details
Double blinded by closed envelops
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
PhDTropical Medicine

Study Record Dates

First Submitted

May 11, 2017

First Posted

May 12, 2017

Study Start

January 1, 2017

Primary Completion

June 1, 2017

Study Completion

June 30, 2017

Last Updated

March 13, 2026

Record last verified: 2026-03

Locations

EG(1)